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Although high-dose rifampicin holds promise for improving tuberculosis control by
potentially shortening treatment duration, these effects attributed to eradication of
persistent bacteria are unclear. The presence of persistent Mycobacterium tuberculosis
was examined using resuscitation promoting factors (RPFs) in both in vitro hypoxia and
in vivo murine tuberculosis models before and after treatment with incremental doses
of rifampicin. Pharmacokinetic parameters and dose-dependent profile of rifampicin in
the murine model were determined. The Cornell mouse model was used to test efficacy
of high-dose rifampicin in combination with isoniazid and pyrazinamide and to measure
relapse rate. There were large numbers of RPF-dependent persisters in vitro and in
vivo. Stationary phase cultures were tolerant to rifampicin while higher concentrations of
rifampicin eradicated plate count positive but not RPF-dependent persistent bacteria.
In murine infection model, incremental doses of rifampicin exhibited a dose-dependent
eradication of RPF-dependent persisters. Increasing the dose of rifampicin significantly
reduced the risk of antibiotic resistance emergence. In Cornell model, mice treated
with high-dose rifampicin regimen resulted in faster visceral clearance; organs were
M. tuberculosis free 8 weeks post-treatment compared to 14 weeks with standard-
dose rifampicin regimen. Organ sterility, plate count and RPF-dependent persister
negative, was achieved. There was no disease relapse compared to the standard
dose regimen (87.5%). High-dose rifampicin therapy results in eradication of RPF-
dependent persisters, allowing shorter treatment duration without disease relapse.
Optimizing rifampicin to its maximal efficacy with acceptable side-effect profiles will
provide valuable information in human studies and can potentially improve current
tuberculosis chemotherapy.
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Introduction
Tuberculosis remains a major cause of mortality worldwide
(World Health Organization [WHO], 2010). Eﬀective
disease control is hindered by bacterial persistence, which
necessitates prolonged multi-agent antimicrobial therapy;
leading to poor patient compliance, high relapse rates and
drug-resistance (Mitchison, 2005). Thus, shortening the
duration of chemotherapy is of signiﬁcant clinical beneﬁt.
Drug discovery, although exciting, is arduous, expensive, and
time-consuming (Nunn et al., 2008; van Niekerk and Ginsberg,
2009). Therefore, increasing the therapeutic dose of currently
marketed antibiotics represents an innovative concept. Of the
current anti-tuberculous drugs, only rifampicin is eﬀective
against persistent Mycobacterium tuberculosis (Mitchison, 1985;
Hu et al., 2000; Mitchison, 2000; Mitchison and Fourie, 2010) and
has favorable toxicity proﬁle to be used at higher doses (Girling,
1978; Yew and Leung, 2006). Previous studies showed that
high-dose rifampicin therapy up to 35 mg/kg is well-tolerated in
man (Kreis et al., 1976; Diacon et al., 2007; Boeree et al., 2013)
and increases the rate of tuberculosis clearance (Kreis et al.,
1976). Similar observations were made in mice (Jayaram et al.,
2003; Rosenthal et al., 2012; de Steenwinkel et al., 2013), with a
maximum tolerable dose of 160 mg/kg per day (de Steenwinkel
et al., 2013). However, whether these eﬀects are attributed to
eradication of persistent bacteria, the fundamental problem
preventing eﬀective disease control, is unclear.
In this study, we hypothesed that high-dose rifampicin in the
current tuberculosis therapy would be [1] eﬀective in eradicating
persistent M. tuberculosis and [2] prevent emergence of drug
resistance and disease relapse. To this end, we rigorously studied
the therapeutic eﬀects of incremental doses of rifampicin singly
or in combination with isoniazid and pyrazinamide on both in
intro and in vivomodels of bacterial persistence.
Materials and Methods
In Vitro Hypoxia Model
M. tuberculosis strain H37Rv was grown in 7H9 medium
containing 0.05% Tween 80 supplemented with 10% albumin
dextrose complex (ADC; Becton and Dickinson, UK) at 37◦C
without disturbance for 200 days (Hu et al., 2000). At diﬀerent
time point, CFU counts were performed by plating a serial
of 10-folds dilutions of the cultures on 7H11 agar medium
supplemented with oleic albumin dextrose complex (OADC,
Becton and Dickinson, UK). The 7H11 agar plates were made
according to the manufacturer’s instruction. The quality control
of the plates for each batch was made by plating a serial 10-
folds dilution of a log phase M. tuberculosis culture on the agar
plates and compared with the 7H11 agar plates from Becton
and Dickinson, UK. Colonies were counted after incubation of
the plates at 37◦C for 3–4 weeks and viability was expressed as
Log CFU/ml. The susceptibility patterns of the strain to anti-TB
drugs deﬁned as minimum inhibitory concentration (MIC) are
listed as following: rifampicin 0.5 mg/L, rifabutin 0.0625 mg/L,
rifapentine 0.25 mg/L, isoniazid 0.25 mg/L, ethambutol 2 mg/L,
streptomycin 2 mg/L, para-aminosalicylic acid 0.5 mg/L and
pyrazinamide > 512 mg/L (pH 5.5–5.6).
Antibiotic Exposure In Vitro
Rifampicin (Sanoﬁ Aventis) at diﬀerent concentrations was
added into log-phase and stationary-phase cultures in the
hypoxia model and incubated at 37◦C. At diﬀerent time point,
the cultures were washed with phosphate buﬀered saline (PBS)
for three times and viability was determined using CFU counts or
broth counts.
Resuscitation of M. Tuberculosis
For resuscitation of M. tuberculosis grown in vitro and in
vivo, culture supernatant containing resuscitation promoting
factors (RPFs) or 7H9 medium was used as described previously
(Mukamolova et al., 2010). M. tuberculosis H37Rv was grown
in 7H9 medium for 15–20 days until an optical density of 1
was reached. The cultures were harvested by centrifugation at
3000 g for 15 min and ﬁltered with 0.2 µm ﬁlter (Sartorius)
twice. The sterilized culture ﬁltrates were used immediately for
the broth counting of the most probable number (MPN) of
the bacilli. Broth counting was performed as serial 10-folds
dilutions in triplicate in which 0.5 ml of in vitro cultures
were added to 4.5 ml of the culture ﬁltrates or 0.3 ml of
tissue homogenates to 2.7 ml of the culture ﬁltrates. At 10-
days intervals over a 2-months period of incubation at 37◦C,
the broth cultures were examined for visible turbidity. Growth
of M. tuberculosis in turbid tubes was conﬁrmed by colonial
morphology on 7H11 agar plates. The MPN of viable bacilli
was then estimated from the patterns of positive and negative
tubes (Mukamolova et al., 2010). The absence of microorganisms
other than mycobacteria from turbid tubes was shown by plating
on blood agar medium (Oxoid) and sabouraud dextrose agar
(Oxoid).
Pharmacokinetic of Rifampicin in BALB/S Mice
Pharmacokinetic (PK) of rifampicin in non-infected mice was
determined by dosing-ranging studies. Rifampicin at 0, 10, 20,
30, 40, and 50 mg/kg body weight was administered orally
with a single dose by gavage to three BALB/c mice (6–8 weeks
old, female) which were obtained from Harlan UK Ltd. Serial
venous blood samples (20 µl) were collected at various time
points from 1, 2, 3, 4, 5, 6, 7, 8 and 24 h post-treatment by tail
puncture and mixed with 40 µl of water. The blood samples
were stored at −80◦C and subsequently transported in dry ice
to GlaxoSmithKline for bioanalysis and PK calculations. Three
animals were used for the entire blood sampling process. The
concentration of rifampicin in the blood was determined by
UPLC-MSMS assay. PK analysis was performed with Phoenix
WinNonLin software (version 6.3; Pharsight, USA). The PK
parameters were calculated using a non-compartmental analysis
(NCA) model.
Rifampicin Monotherapy in Mouse Model
Rifampicin was tested with ﬁve diﬀerent doses singly for 12 weeks
in BALB/c mice (6–8 weeks old, female). The mice were infected
intravenously with 1.2 × 105 CFU of the M. tuberculosis
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H37Rv which was mouse-passaged to retain the virulence of
the strain. Spleens and lungs from four mice were removed
rapidly after sacriﬁce and sterile autopsy performed at timepoint
zero. CFU counts of the organs were performed from serial 10-
folds dilutions of the homogenate on plates of selective 7H11
medium and incubated at 37◦C for 3–4 weeks. At 2 weeks
after infection, the mice were treated with 10, 15, 20, 30, and
50 mg/kg of rifampicin 5 days/week for 12 weeks. At 2nd, 4th,
6th, 8th, 10th, and 12th weeks post-treatment, organ CFU counts
from four mice from each treatment group were determined. All
animal experiments were performed according to the Animals
Scientiﬁc Procedures Act, 1986 (an Act of the Parliament of the
United Kingdom 1986 c. 14; HomeOﬃce Project licence Number
70/7077) with approval from St George’s, University of London
ethics committee. The animal husbandry guidelines and animal
procedure for this study were followed according to the Animals
Scientiﬁc Procedures Act, 1986.
Selection of Rifampicin-Resistant Mutants In
Vivo
At 8th, 10th, and 12th weeks post-treatment, the lung and spleen
homogenates were plated on 7H11 plates containing rifampicin
concentration at a serial of twofolds dilution from 0 to 64 mg/L.
Colonies from the plates containing MIC value higher than
fourfolds were picked and regrown in 7H9 medium. MIC was
retested on rifampicin containing 7H11 agar plates.
Cornell Model
For the combination of rifampicin with isoniazid and
pyrazinamide, the Cornell mouse model was used as described
previously (McCune and Tompsett, 1956; McCune et al., 1966;
Hu et al., 2000). Brieﬂy, at 3 weeks after M. tuberculosis H37Rv
infection, treatment was given to female BALB/c mice for
14 weeks with 150 mg/kg pyrazinamide, 25 mg/kg isoniazid
combined with 10 or 50 mg/kg rifampicin by daily oral
administration for 5 days per week. A sample of four mice was
sacriﬁced at the 2nd, 4th, and 6th weeks and a sample of 10 mice
was sacriﬁced 8th, 11th, and 14th weeks of treatment to monitor
CFU counts. The organ homogenates from the 14th weeks were
cultured in selective Kirchner liquid medium by the addition of
polymyxin B 200 U/ml, carbenicillin 100 mg/L, trimethoprim
20 mg/L, and amphotericin B 10 mg/L (Selectatab, Mast
Diagnostica GmbH) for 4 weeks with subsequent sub-culturing
onto selective Löwenstein-Jensen slopes for a further 4 weeks.
Immediately after termination of 14 weeks of chemotherapy,
the remaining mice were administered 0.5 mg/mouse of
hydrocortisone acetate (McCune et al., 1966) by daily oral
administration for 8 weeks to inhibit the host immune response,
CFU counts from lungs and spleens were performed from serial
10-folds dilutions of the homogenate and the entire homogenates
of the organs were also plated on 7H11 agar plates to determine
disease relapse.
Statistical Analysis
The diﬀerence between diﬀerent experimental groups was
determined by analysis of variance (ANOVA) and Student’s t-test.
The diﬀerence between the relapse rates was determined by
Chi-square test. P-values< 0.05 were considered signiﬁcant.
Results
RPF-Supernatant Resuscitates Persistent
M. Tuberculosis Growth In Vitro
In the in vitro hypoxic model (Wayne, 1976), exponential
growth was observed up to 15 days, followed by growth
stabilization until day 60, when a 2-log reduction of CFU
counts occurred lasting up to day 200 (Figure 1). To determine
the cause of this count reduction (cell death or viable but
non-culturable state), log-phase and stationary phase culture
were incubated with the supernatant of a late log-phase
culture containing RPF or 7H9 (Mukamolova et al., 2010).
These RPF-supernatant or 7H9 medium resuscitated cultures
were quantiﬁed using the MPN method. Interestingly, at the
time points selected for comparison (14, 35, 45, 60, 70,
80, 120, and 200 days), RPF-supernatant resuscitated cultures
displayed progressively higher broth counts than the CFU
counts (0.08, 0.23, 0. 30, 0.45, 1.28, 1.51, 1.99, and 2.03
logs, respectively; Figure 1) compared to those of cultures
resuscitated by 7H9 (−0.08, 0.00, 0.13, 0.15, 0.72, 0.82, 0.99
and 0.96 logs, respectively; Figure 1). The 7H9 or RPF-
dependent persisters were unable to form colonies during
prolonged incubation periods. Signiﬁcant diﬀerences were
observed amongst CFU counts, 7H9 broth counts and RPF
broth counts (P < 0.001 to 0.0001) determined by ANOVA
analysis.
FIGURE 1 | Resuscitation of RPF-dependent tubercle bacilli from the
in vitro hypoxic model ofM. tuberculosis. M. tuberculosis H37Rv was
grown in 7H9 medium without disturbance for 200 days. CFU counts were
performed at different time points in triplicate (line with empty squares). MPN
counts from cultures of 14, 35, 45, 60, 70, 80, 120, and 200 days were
performed with 7H9 medium (line with solid circles) or the culture filtrate (line
with solid squares). These experiments were performed three times with
reproducible results. ANOVA analysis demonstrated that there were significant
differences amongst CFU counts, 7H9 broth counts and RPF broth counts
(∗∗∗P < 0.001 to 0.0001).
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Higher Concentration of Rifampicin was
Required to Treat, but not Eradicate,
M. Tuberculosis in Stationary Phase In Vitro
To determine the optimal concentration of rifampicin required
to clear stationary-phase bacteria, we examined the eﬀect
of incremental drug concentrations on both log- (7 days)
and stationary-phase (60 days) cultures; see Figure 2. In
log-phase cultures, apparent bacterial clearance was achieved
at/before 20 days with rifampicin concentrations of >2 mg/L
(Figure 2A). However, to achieve the same antimicrobial
eﬀect in stationary-phase cultures, signiﬁcantly higher drug
concentrations (>32 mg/L) were required (Figure 2B).
To delineate the level of residual viable M. tuberculosis
remaining after apparent bacterial clearance with high
concentration rifampicin treatment, we incubated 100-days
cultures with incremental concentrations of rifampicin (12.5,
25, 50, and 100 mg/L) for 5 days. After resuscitation with RPF-
culture ﬁltrate, viable bacteria were salvageable from all cultures
and increased with reducing concentrations of rifampicin
treatment (Figure 2C). Importantly, the apparent bacterial
clearance produced by a 5-days treatment with 100 mg/L
rifampicin showed a 2-log resuscitatable growth count with
RPF-culture ﬁltrate (Figure 2C). This reﬂects the diﬃculties in
completely eradicating M. tuberculosis, even with extremely high
rifampicin concentrations, in vitro.
RPF-Supernatant Resuscitates Persistent
M. Tuberculosis Growth In Vivo
We previously showed that M. tuberculosis enters stationary-
phase growth after ∼2–3 weeks of infection in mice (Hu et al.,
2006). In order to investigate the growth behavior of stationary-
phase bacteria in vivo, we incubated murine lung homogenates
from 2, 6, 11, 12, and 14 weeks of M. tuberculosis infection
with 7H9 medium or RPF-culture ﬁltrate and determined the
bacilli MPN. As illustrated in Figure 3, 7H9 medium resuscitated
cultures showed higher broth counts than the CFU counts from
mouse lungs (0.26, 0.45, 0.65, 0.68, and 1.00 logs, respectively).
In contrast, RPF-supernatant resuscitated cultures displayed
progressively higher broth counts than the CFU counts from
the organ (0.81, 1.24, 1.58, 1.69, and 2.00 logs, respectively).
This is the ﬁrst selective demonstration of viable RPF-dependent
bacilli in murine tuberculosis infection. There were signiﬁcant
diﬀerences amongst CFU counts, 7H9 broth counts and RPF
broth counts (P < 0.001) in mice determined by ANOVA
analysis.
Pharmacokinetic of Rifampicin
Rifampicin plasma concentration time curves examined over a
period of 24 h in BALB/c mice (Table 1) indicated a dose-
proportional increase in maximal concentration of rifampicin
(Cmax) and drug exposure (AUC; Table 1). This implies the free
(protein unbound) fraction of rifampicin in plasma. Interestingly,
Tmax was shortened with the increased dosage of the drug.
Effect of High-Dose Rifampicin In Vivo
We investigated the eﬀect of rifampicin dose increments on the
rate of bacterial eradication and emergence of drug resistance.
FIGURE 2 | Determination of rifampicin activity against log-phase and
stationary-phaseM. tuberculosis using time kill curve analysis.
Rifampicin at the concentration from 16 to 0 mg/L were incubated with a
7 days log-phase culture (A) and rifampicin at the concentration from 64 to
0 mg/L were incubated with the 60 days stationary-phase culture (B). CFU
counts were estimated at different time points. A 100-days culture was
treated with 12.5, 25, 50, and 100 mg/L of rifampicin for 5 days. After removal
of rifampicin, the treated culture were subject to CFU counting on agar plates
and MPN counting with the culture filtrates (C). These experiments were
performed three times with reproducible results. Statistical analysis
demonstrated that the decline of CFU counts after treatment with different
concentrations of rifampicin was significant, P < 0.0008 (ANOVA), for the
log-phase culture (A), P < 0.001 (ANOVA) for the stationary phase culture (B)
and P < 0.001 (∗∗∗ Student’s t-test) for the 100-days culture (C).
Frontiers in Microbiology | www.frontiersin.org 4 June 2015 | Volume 6 | Article 641
Hu et al. High-dose rifampicin kills persisters
FIGURE 3 | Resuscitation ofM. tuberculosis grown in mouse lungs.
BALB/c mice were infected with M. tuberculosis. Viability of the bacilli in lung
was determined by CFU counting and MPN counting with 7H9 or the culture
filtrates at 2, 6, 10, 12, and 14 weeks post-infection. The results have been
performed twice with reproducible results. ANOVA analysis demonstrated that
there were significant differences amongst CFU counts, 7H9 broth counts and
RPF broth counts (∗∗∗P < 0.001) in mice.
TABLE 1 | Blood pharmacokinetics parameters of rifampicin in BALB/c
mice.
Dose
(mg/kg)
Cmax
(mg/L)
Tmax (h) AUC0−24 h
(mg∗h/L)
AUCinf
(mg∗h/L)
10 11 ± 2 2.7 121 ± 10 162 ± 29
20 21 ± 1 2.3 228 ± 28 259 ± 36
30 32 ± 2 2 332 ± 31 370 ± 43
40 48 ± 4 1.7 530 ± 33 598 ± 58
50 52 ± 10 1 600 ± 81 739 ± 72
Cmax, maximum blood concentration; Tmax, time to maximum concentration;
AUC0−24 h, area under the curve from rifampicin administration to 24 h; AUCinf,
area under the curve from rifampicin administration to the infinite time. The values
are expressed, except for Tmax, as mean (standard deviation) of the values derived
from three mice.
At 10 mg/kg, the rate of pulmonary bacterial eradication was
slow (99% kill at 8 weeks followed by a plateau). Treatment
with 15 mg/kg doubled the rate of bacterial eradication (99%
kill at 4 weeks). Both doses failed to achieve undetectable
M. tuberculosis CFU counts in murine lungs after 12 weeks
treatment. Undetectable CFU counts in lungs were achieved with
20, 30, and 50 mg/kg of rifampicin treatment for 12, 10, and
6 weeks, respectively (Figure 4A). A similar dose response trend
was observed in spleen (Figure 4B). No outward signs of toxicity
or abnormal behavior were observed in any mice treated with
rifampicin.
No rifampicin-resistant strains were detected for the 15, 20,
30, and 50 mg/kg treatment groups. The isolates were susceptible
to rifampicin with a MIC at 0.5 mg/L. However, for the 10 mg/kg
group, at 8 weeks of treatment, rifampicin resistant strains were
isolated from spleen of one out of four mice showing MIC at
2 mg/L. At 10 and 12 weeks, resistant strains were found from
lung or spleen of two out of four mice showing MIC at 4–8 mg/L.
These data were excluded from Figure 4.
FIGURE 4 | Viability of M. tuberculosis H37Rv in BALB/c mice after
rifampicin treatment. The results of a single experiment are shown with
viability expressed as log CFU counts per lung (A) and spleen (B). Mice were
infected intravenously and the infection was allowed to progress for 2 weeks
prior to treatment with rifampicin at 10, 15, 20, 30 and 50 mg/kg indicated as
a solid arrow for 12 weeks (time weeks 0–12). At week 2, 4, 6, 8, and 12 of
post-treatment, four mice from each group were sacrificed for CFU counting.
Data of the mice containing rifampicin-resistant strains for the 10 mg/kg group
was excluded. ANOVA analysis demonstrated that the decline of CFU counts
after treatment with different concentrations of rifampicin was significant in
lungs P < 0.02 and in spleens P < 0.04.
To investigate the eﬀects of increased dosage of rifampicin
(10–50 mg/kg) on the post-treatment levels of persisters through
RPF-induced resuscitation, we incubated lung and spleen
homogenies at 6 and 12 weeks of antibiotic treatment with the
culture ﬁltrates. At 6 weeks post-treatment, only 50 mg/kg of
rifampicin rendered lung CFU counts to zero, but 0.56 logs
of RPF-resuscitable bacilli remained (Table 2). At 12 weeks
post-treatment, incremental doses of rifampicin at 20, 30,
and 50 mg/kg resulted in more eﬀective elimination of RPF-
dependent bacilli (1.33, 0.96, and <0.01 log cells/lung, 1.27,
1.09, and 0.5 log cells/spleen, respectively) after CFU counts
in these organs were rendered negative (Table 2). Importantly,
pulmonary sterility was observed after 12 weeks of high-dose
rifampicin (50 mg/kg) treatment.
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TABLE 2 | Resuscitation ofM. tuberculosis H37Rv in mouse lungs and spleens after treatment with different concentration of rifampicin.
Lung Spleen
Treatment
(mg/kg)
Weeks∗ Plate counts (log
CFU/lung)
Broth counts RPF† (log
cells/lung)
Plate counts (log
CFU/spleen)
Broth counts RPF‡ (log
cells/spleen)
10 6 5.75 ± 0.11 7.49 ± 0.51 5.63 ± 0.29 7.36 ± 0.20
15 6 4.55 ± 0.14 5.97 ± 0.12 4.06 ± 0.13 5.28 ± 0.07
20 6 3.93 ± 0.09 5.02 ± 0.04 3.46 ± 0.19 4.53 ± 0.60
30 6 3.11 ± 0.39 4.09 ± 0.20 3.06 ± 0.58 4.06 ± 0.24
50 6 0 0.56 ± 0.23 0.38 ± 1.06 0.99 ± 0.45
10 12 4.98 ± 0.04 6.92 ± 0.22 5.03 ± 0.03 6.58 ± 0.50
15 12 2.41 ± 0.39 3.89 ± 0.23 2.09 ± 0.10 3.40 ± 0.40
20 12 0 1.33 ± 0.04 0 1.27 ± 0.98
30 12 0 0.96 ± 0.40 0 1.09 ± 0.47
50 12 0 <0.01 0 0.50 ± 0.05
RPF, resuscitation promoting factors; MPN, most probable number; ∗Weeks of rifampicin treatment. †,‡Determined by MPN of the diluted lung and spleen homogenies
with the culture supernatants containing RPF; <0.01, no bacilli were present in all sets of dilution tubes. Mean of MPN from three mice.
High-Dose of Rifampicin in the Cornell Model
We compared the eﬃcacy of high-dose (50 mg/kg) vs. low-
dose (10 mg/kg) rifampicin in combination regimens with
ﬁxed standard doses of isoniazid (25 mg/kg) and pyrazinamide
(150 mg/kg) in a well-deﬁned tuberculosis model – the Cornell
model. In terms of lung CFU counts, a 99% bacterial eradication
(2-log reduction) was achieved more rapidly after treatment
with high-dose (2 weeks) compared to low-dose (3.4 weeks)
combination regimens. To achieve negative CFU counts in lungs,
a longer period of treatment was required for the low-dose
(14 weeks) compared to high-dose (8 weeks) regimen. This is
shown in Figure 5A. In the sterile organs, no tubercle bacilli
were recovered as conﬁrmed by negative cultures of the organ
homogenates in selective Kirchner broth for 4 weeks. Similar
treatment proﬁles were seen in spleens (Figure 5B) except CFU
count negativity was achieved slightly earlier in the high-dose
treated group (6 weeks) compared to in lungs.
In order to investigate the eﬀect of high-dose vs. low-dose
regimens on the post-treatment level of persisters through RPF-
induced resuscitation, lung homogenates at 8 and 14 weeks post-
treatment were incubated with supernatants containing RPFs. At
8 weeks of treatment with the low-dose regimen, high levels of
both bacterial CFU counts (2.32-logs in lungs; 1.99-logs in spleen)
and RPF-resuscitated bacilli (3.88-log cells in lungs; 3.71-log
cells in spleen) remained. At 14 weeks post-treatment, although
CFU counts were negative, there were signiﬁcant levels of RPF-
resuscitated bacilli in lungs and spleens (1.41-log cells in lungs;
1.61-log cells in spleen). Treatment with high-dose regimen at
both 8 and 14 weeks led to complete eradication of bacterial CFU
counts. RPF-resuscitated bacilli (0.8-log) were only detectable in
spleens at 8 weeks post-treatment. This eﬀect is shown in Table 3.
Relapse Rate after Treatment with the
Regimens Containing Different Doses of
Rifampicin in the Cornell Model
After 8 weeks of high dosage steroid immunosuppression which
reactivated latent TB (McCune et al., 1966), disease relapse rates
for the two dose rifampicin regimen treatments were determined
by the percentage of mice that developed positiveM. tuberculosis
cultures in lungs, spleens or both. The organ CFU counts are
shown in Table 4. The treatment with the regimen containing
10 mg/kg of rifampicin gave rise to M. tuberculosis positive
organs in 21 out of 24 mice (87.5% relapse rate). In contrast,
treatment with the regimen containing high-dose of rifampicin
at 50 mg/kg resulted in zero counts in the organs showing relapse
free (P < 0.001).
Discussion
A persister-eradicating drug regimen with a short duration
of therapy would represent the most important advantage in
tuberculosis treatment. To our knowledge, this study is the
ﬁrst to demonstrate, in the Cornell model, that combination
therapy containing high-dose rifampicin (50 mg/kg) eradicates
persistent bacilli, shortens treatment duration and reduces
disease relapse. Furthermore, high-dose rifampicin treatment
reduces the emergence of antibiotic resistance.
In vitro, M. tuberculosis persistence is driven by hypoxia
(Wayne, 1994). In the in vitro stationary-phase model (Wayne,
1976, 1977; Hu et al., 2000), the bacilli grow initially in the
top layer of an unagitated culture, where oxygen is available.
They slowly adapt to microaerophilic and eventually to anaerobic
conditions while sinking down in the medium and ﬁnally settling
on the bottom of the containers (Hu et al., 1999). At 30–
40 days, replication cannot be detected (Wayne, 1976, 1977).
In late stationary-phase cultures after 60 days of incubation,
protein synthesis is switched oﬀ (Hu et al., 1998). Interestingly,
the data shown in the present paper indicates that the majority
of bacilli entered into a viable but non-culturable stage (plate
count negative), some of which was detected using 7H9 broth.
However, a subpopulation of persistent M. tuberculosis was only
resuscitated using the supernatant from actively growing cultures
containing RPF (Figure 1). It has been shown that RPFs are
bacterial self-generated stimulating proteins (Mukamolova et al.,
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FIGURE 5 | Viability ofM. tuberculosis H37Rv in the mouse Cornell
model of dormancy. The results of a single experiment are shown with
viability expressed as log CFU counts per lung (A) and spleen (B). Mice were
infected intravenously at week –3 and the infection was allowed to progress
for 3 weeks prior to treatment with isoniazid and pyrazinamide with rifampicin
added at 10 or 50 mg/kg indicated as a solid arrow for 14 weeks (time weeks
0–14). At week 2, 4, 6, 8, 11, and 14 of post-treatment, CFU counts in the
organs from each group were estimated. Steroid treatment was started
immediately after the termination of 14 weeks of antibiotic treatment as
indicated with an empty arrow. The experiment has been performed twice
with reproducible results. Statistical analysis demonstrated that the decline of
CFU counts in lungs and spleens was significant between low and high-dose
rifampicin regiments, ∗∗∗P < 0.0001 or ∗∗P < 0.02 (Student’s t-test).
1998) which not only facilitate the growth of young cultures but
wake up dormant cells in vitro (Shleeva et al., 2002) and in TB
patients’ sputa (Mukamolova et al., 2010). We conclude that the
decline in CFU counts after 60 days of incubation (Figure 1) was
not due to bacterial death, because the total viable cells (CFU
counts and broth counts detected by RPF) remained constant
(Figure 1).
In a murine infection model (Hu et al., 2006; Hu and Coates,
2009), it has been shown that the animal’s immune response
restricts bacterial growth after 2–3 weeks of infection but fails
to eliminate the infection driving the bacteria into an in vivo
stationary phase. It has been reported that during chronic
infection in mice, M. tuberculosis replicates and dies leading
to a dynamic balanced growth (Gill et al., 2009). Our results
showed that considerable amounts of bacilli, at least 15-folds
more than CFU count positive bacteria, converted into RPF
dependent and plate count negative persisters (Figure 3). 7H9
medium only resuscitated ﬁvefolds of the plate count negative
persisters. Our data conﬁrmed that traditional viable counting
methods greatly underestimate the actual numbers of viable
cells. We previously demonstrated, by mRNA detection using
reverse transcriptase polymerase chain reaction and [3H]uridine
incorporation, that ongoing transcription continues in persistent
M. tuberculosis in the sterile organs of the Cornell model (Hu
et al., 2000). These results indicate that the persistent bacilli were
metabolically active. It is not known if the persistent organisms
we detected previously were the same as the RPF dependent
persisters. These persistent bacteria contribute a major problem
to the development of eﬀective and shortened chemotherapy.
In vitro, stationary-phase cultures are profoundly tolerant
to rifampicin. A 16-folds higher concentration of rifampicin
(32 mg/L) was required to eradicate CFU count positive
organisms compared to log phase bacteria (2 mg/L; Figure 2).
Importantly, RPF dependent persisters in 100 days stationary-
phase cultures could not be eliminated with even ultra-high
concentrations of rifampicin (100 mg/L; Figure 2C). In mice,
while increased doses of rifampicin alone after prolonged
treatment were able to achieve organ CFU count negativity and
reduced RPF-dependent bacteria; only high-dose of rifampicin
(50 mg/kg) was able to eradicate the persisters in lungs (Table 3).
Furthermore, we have shown here that in the Cornell model,
high-dose rifampicin regimen eliminates all persisters, even the
RPF dependent subpopulation (Table 4).
It has been found that in human tuberculosis prior to
treatment, smear-positive sputa contained a considerable amount
of RPF dependent persisters (Mukamolova et al., 2010).
Furthermore, the numbers of RPF-dependent persisters was
enhanced after standard chemotherapy compared with the plate
counts positive populations (Mukamolova et al., 2010). It is not
known whether the persisters we found in vitro and in vivo
were the same as those in humans and if rifampicin treatment
in mice necessarily predicts the situation with rifampicin in
humans. We have recently highlighted (Coates et al., 2013)
contradictory results with high-dosage rifamycin in mice and
humans. Tuberculosis infections are diﬀerent between mice and
man, not least the absence of caseating granulomas in mice.
Therefore, the interpretation of our data and the subsequent
translation into human studies need to be undertaken with
caution.
It has been proposed recently (Mitchison, 2012) that peak drug
concentrations are better indicators than AUC for predicting
higher degrees of persister-eradication and lower relapse rates.
This is based on TB patients (rapid or slow acetylators) treated
with isoniazid in whom the magnitude of clinical response was
related to peak concentration of the drug (Mitchison, 2012).
Repeated peaks can kill low-level resistant mutants. The same
may be true for rifampicin (Mitchison, 2012) because repeated
peak concentrations of rifamycins kill low antibiotic-tolerant
persisters (Hu et al., 2000; Mitchison, 2012). Our results show
that the PK value at 10 mg/kg gave a Cmax in blood of
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TABLE 3 | Resuscitation ofM. tuberculosis H37Rv in mouse lungs and spleens of Cornell model after treatment with the 10 and 50 mg/kg rifampicin
regimens.
Lung Spleen
Treatment
group
Weeks∗ Plate counts
(log CFU/lung)
Broth counts RPF†
(log cells/lung)
Plate counts (log
CFU/spleen)
Broth counts RPF‡
(log cells/spleen)
R10HZ 8 2.32 ± 0.24 3.88 ± 0.39 1.99 ± 0.07 3.71 ± 0.37
14 0 1.41 ± 0.12 0 1.61 ± 0.29
R50HZ 8 0 <0.01 0 0.80 ± 0.36
14 0 <0.01 0 <0.01
∗Weeks of treatment. †,‡Determined by MPN of the diluted lung and spleen homogenies with the culture supernatants containing RPF; <0.01, no bacilli were present in
all sets of dilution tubes. Mean of MPN from four mice.
TABLE 4 | Organ CFU counts after 8 weeks of steroid treatment.
Positive culture from R10HZ R50HZ
Spleen only 11 0
Lung only 5 0
Both organs 5 0
Neither organs∗ 3 28
Total 24 28
Relapse (%) 87.5 0
R10HZ, Rifampicin 10 mg/kg, Isoniazid 25 mg/kg, Pyrazinamide 150 mg/kg
for 14 weeks; R50HZ, Rifampicin 50 mg/kg, Isoniazid 25 mg/kg, Pyrazinamide
150 mg/kg for 14 weeks. ∗Plate and broth count negative.
11 mg/L and an AUC0−24 h of 121 mg h/L which was very
similar to those of previous studies in mice (Rosenthal et al.,
2012; de Steenwinkel et al., 2013) and in humans (Doble et al.,
1988; Sirgel et al., 2005). The PK values of rifampicin increased
proportionally with increasing doses of rifampicin which was
also in agreement with previous murine study (Rosenthal et al.,
2012; de Steenwinkel et al., 2013). Although standard doses of
rifampicin achieved a blood level of 11 mg/L, only 3.3% of free
drug (de Steenwinkel et al., 2013) was able to diﬀuse to the
lesion and inhibit bacterial growth as 97–98% of rifampicin or
rifapentine was bound to plasma protein (Mitchison, 1998; de
Steenwinkel et al., 2013). This suggests that a standard dose of
rifampicin is not high enough to kill persistent organisms which
are present at the beginning of the treatment and formed during
the antibiotic treatment. In the murine model, we showed here
that increasing dose of rifampicin exhibited an accelerated dose-
dependent eradication of persistent bacteria (Table 3). When
the rifampicin concentration was increased to 30 mg/kg or
higher, high blood Cmax was achieved, leading to a higher
level of biological available rifampicin which was able to remove
persistent bacteria (Mitchison, 2012).
We showed rifampicin resistance appeared after 8 weeks
of standard rifampicin treatment (10 mg/kg) in mice which
was exacerbated by increasing the duration of therapy. This
concurs with previous evidence that prolonged anti-TB drug
exposure and higher bacterial burdens predict the emergence
of antibiotic resistance (de Steenwinkel et al., 2010). In certain
countries, standard anti-TB drug regimens rendered a low 2-
months sputum culture conversion rate (between 50 and 70%)
which led to acquired drug resistance (Abdool Karim et al., 2010;
Calver et al., 2010). The development of rifampicin resistance
was strongly associated with lower serum drug concentrations
(Pasipanodya et al., 2013), while higher Cmax and AUC inhibited
rifampicin resistance (Gumbo et al., 2007). Importantly, we
show here that higher doses of rifampicin (>15 mg/kg) induced
rapid bacterial eradication with undetectable resistant bacilli.
Increasing the dose of rifampicin signiﬁcantly reduced the risk
of antibiotic resistance emergence. The precise reason for this
mechanism is unclear; we speculate it relates to the fact that
dead, and possibly, metabolically inhibited bacteria are unable to
mutate.
We present unprecedented evidence that true TB-sterility,
i.e., negative CFU count and RPF-resuscitatable cultures, can be
achieved in lungs and spleens after 8 and 14 weeks of combination
chemotherapy containing high-dose rifampicin (50 mg/kg). For
the ﬁrst time, we oﬀer a possible mechanistic insight into this
observation. This builds signiﬁcantly on existing evidence that
suggests that high-dose rifampicin shortens treatment duration
from 14 to 8 weeks (Rosenthal et al., 2012; de Steenwinkel et al.,
2013). Our ﬁndings show that RPF-dependent bacilli constitute
a major pool for disease relapse in the mouse Cornell model,
not only the culturable but also the non-culturable bacilli are
eradicated, the treatment period is shortened and disease relapse
rate is reduced.
Conclusion
We demonstrated that RPF-dependent persistent M. tuberculosis
was formed in vitro and in vivo. The current recommended
dosage of 10 mg/kg is insuﬃcient to kill persistent bacilli.
Higher doses of rifampicin alone or in combination with
isoniazid and pyrazinamide signiﬁcantly shortened the treatment
period and eliminated disease relapse by removing persistent
bacteria. Optimizing rifampicin to its maximal therapeutic
eﬃcacy with acceptable side-eﬀect proﬁles will provide valuable
information in human studies and can potentially improve
current tuberculosis chemotherapy.
Acknowledgments
This work was supported by the Innovative Medicines Initiative
Joint Undertaking resources of which are composed of ﬁnancial
contribution from the European Union’s Seventh Framework
Frontiers in Microbiology | www.frontiersin.org 8 June 2015 | Volume 6 | Article 641
Hu et al. High-dose rifampicin kills persisters
Programme (FP7/2007-2013) and EFPIA companies’ in kind
contribution (grant number 115337). The publication reﬂects
only the author’s views. The European Commission is not liable
for any use that may be made of the information herein. The
authors would also like to thank Yingjun Liu for his assistance
in this work.
References
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C.,
Gray, A., et al. (2010). Timing of initiation of antiretroviral drugs during
tuberculosis therapy. N. Engl. J. Med. 362, 697–706. doi: 10.1056/NEJMoa09
05848
Boeree, M. J., Diacon, A., Dawson, R., Van Balen, G. P., Venter, A., Du Bois, J.,
et al. (2013). What is the Right Dose of Rifampin? A Dose Escalating Study.
Available at: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.
2013.187.1_MeetingAbstracts.A3181
Calver, A. D., Falmer, A. A., Murray, M., Strauss, O. J., Streicher, E. M.,
Hanekom, M., et al. (2010). Emergence of increased resistance and extensively
drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg.
Infect. Dis. 16, 264–271. doi: 10.3201/eid1602.090968
Coates, A. R., Hu, Y., Jindani, A., and Mitchison, D. A. (2013). Contradictory
results with high-dosage rifamycin in mice and humans. Antimicrob. Agents
Chemother. 57, 1103. doi: 10.1128/AAC.01705-12
de Steenwinkel, J. E., Aarnoutse, R. E., de Knegt, G. J., Ten Kate, M. T., Teulen, M.,
Verbrugh, H. A., et al. (2013). Optimization of the rifampin dosage to improve
the therapeutic eﬃcacy in tuberculosis treatment, using a murine model.
Am. J. Respir. Crit. Care Med. 187, 1127–1134. doi: 10.1164/rccm.201207-
1210OC
de Steenwinkel, J. E., de Knegt, G. J., ten Kate, M. T., van Belkum, A., Verbrugh,
H. A., Kremer, K., et al. (2010). Time-kill kinetics of anti-tuberculosis drugs,
and emergence of resistance, in relation to metabolic activity ofMycobacterium
tuberculosis. J. Antimicrob. Chemother. 65, 2582–2589. doi: 10.1093/jac/
dkq374
Diacon, A. H., Patientia, R. F., Venter, A., van Helden, P. D., Smith, P. J.,
McIlleron, H., et al. (2007). Early bactericidal activity of high-dose rifampin
in patients with pulmonary tuberculosis evidenced by positive sputum smears.
Antimicrob. Agents Chemother. 51, 2994–2996. doi: 10.1128/AAC.01474-06
Doble, N., Shaw, R., Rowland-Hill, C., Lush, M., Warnock, D. W., and Keal,
E. E. (1988). Pharmacokinetic study of the interaction between rifampicin
and ketoconazole. J. Antimicrob. Chemother. 21, 633–635. doi: 10.1093/jac/
21.5.633
Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., and Sherman,
D. R. (2009). A replication clock for Mycobacterium tuberculosis. Nat. Med. 15,
211–214. doi: 10.1038/nm.1915
Girling, D. J. (1978). The hepatic toxicity of antituberculosis regimens containing
isoniazid, rifampicin and pyrazinamide. Tubercle 59, 13–32. doi: 10.1016/0041-
3879(77)90022-8
Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salﬁnger, M.,
et al. (2007). Concentration-dependentMycobacterium tuberculosis killing and
prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51, 3781–
3788. doi: 10.1128/AAC.01533-06
Hu, Y., Butcher, P. D., Mangan, J. A., Rajandream, M. A., and Coates, A. R.
(1999). Regulation of hmp gene transcription in Mycobacterium tuberculosis:
eﬀects of oxygen limitation and nitrosative and oxidative stress. J. Bacteriol. 181,
3486–3493.
Hu, Y. M., Butcher, P. D., Sole, K., Mitchison, D. A., and Coates, A. R. (1998).
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is
reversed by oxygen or heat shock. FEMS Microbiol. Lett. 158, 139–145. doi:
10.1111/j.1574-6968.1998.tb12813.x
Hu, Y., and Coates, A. R. (2009). Acute and persistentMycobacterium tuberculosis
infections depend on the thiol peroxidase TPX. PLoS ONE 4:e5150. doi:
10.1371/journal.pone.0005150
Hu, Y., Mangan, J. A., Dhillon, J., Sole, K. M., Mitchison, D. A., Butcher,
P. D., et al. (2000). Detection of mRNA transcripts and active transcription
in persistent Mycobacterium tuberculosis induced by exposure to rifampin or
pyrazinamide. J. Bacteriol. 182, 6358–6365. doi: 10.1128/JB.182.22.6358-636
5.2000
Hu, Y., Movahedzadeh, F., Stoker, N. G., and Coates, A. R. (2006). Deletion of the
Mycobacterium tuberculosis alpha-crystallin-like hspX gene causes increased
bacterial growth in vivo. Infect. Immun. 74, 861–868. doi: 10.1128/IAI.74.2.861-
868.2006
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R.,
et al. (2003). Pharmacokinetics-pharmacodynamics of rifampin in an aerosol
infection model of tuberculosis. Antimicrob. Agents Chemother. 47, 2118–2124.
doi: 10.1128/AAC.47.7.2118-2124.2003
Kreis, B., Pretet, S., Birenbaum, J., Guibout, P., Hazeman, J. J., Orin, E., et al. (1976).
Two three-month treatment regimens for pulmonary tuberculosis. Bull. Int.
Union Tuberc. 51, 71–75.
McCune, R. M., Feldmann, F. M., Lambert, H. P., and McDermott, W. (1966).
Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization
in mouse tissues. J. Exp. Med. 123, 445–468. doi: 10.1084/jem.123.3.445
McCune, R. M. Jr., and Tompsett, R. (1956). Fate of Mycobacterium tuberculosis
in mouse tissues as determined by the microbial enumeration technique. I. The
persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged
antimicrobial therapy. J. Exp. Med. 104, 737–762. doi: 10.1084/jem.10
4.5.737
Mitchison, D. A. (1985). The action of antituberculosis drugs in short-
course chemotherapy. Tubercle 66, 219–225. doi: 10.1016/0041-3879(85)9
0040-6
Mitchison, D. A. (1998). Development of rifapentine: the way ahead. Int. J. Tuberc.
Lung Dis. 2, 612–615.
Mitchison, D. A. (2000). Role of individual drugs in the chemotherapy of
tuberculosis. Int. J. Tuberc. Lung Dis. 4, 796–806.
Mitchison, D. A. (2005). Shortening the treatment of tuberculosis. Nat. Biotechnol.
23, 187–188. doi: 10.1038/nbt0205-187
Mitchison, D. A. (2012). Pharmacokinetic/pharmacodynamic parameters and the
choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16, 1186–1189. doi:
10.5588/ijtld.11.0818
Mitchison, D. A., and Fourie, P. B. (2010). The near future: improving the
activity of rifamycins and pyrazinamide. Tuberculosis (Edinb.) 90, 177–181. doi:
10.1016/j.tube.2010.03.005
Mukamolova, G. V., Kaprelyants, A. S., Young, D. I., Young, M., and Kell, D. B.
(1998). A bacterial cytokine. Proc. Natl. Acad. Sci. U.S.A. 95, 8916–8921. doi:
10.1073/pnas.95.15.8916
Mukamolova, G. V., Turapov, O., Malkin, J., Woltmann, G., and Barer, M. R.
(2010). Resuscitation-promoting factors reveal an occult population of tubercle
Bacilli in Sputum. Am. J. Respir. Crit. Care Med. 181, 174–180. doi:
10.1164/rccm.200905-0661OC
Nunn, A. J., Phillips, P. P., and Gillespie, S. H. (2008). Design issues in pivotal drug
trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb.) 88(Suppl. 1),
S85–S92. doi: 10.1016/S1472-9792(08)70039-8
Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., and Gumbo, T.
(2013). Serum drug concentrations predictive of pulmonary tuberculosis
outcomes. J. Infect. Dis. 208, 1464–1473. doi: 10.1093/infdis/jit352
Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli,
K. E., et al. (2012). Dose-ranging comparison of rifampin and rifapentine in
two pathologically distinct murine models of tuberculosis. Antimicrob. Agents
Chemother. 56, 4331–4340. doi: 10.1128/AAC.00912-12
Shleeva, M. O., Bagramyan, K., Telkov, M. V., Mukamolova, G. V., Young, M.,
Kell, D. B., et al. (2002). Formation and resuscitation of “non-culturable”
cells of Rhodococcus rhodochrous andMycobacterium tuberculosis in prolonged
stationary phase.Microbiology (Read. Engl.) 148, 1581–1591.
Sirgel, F. A., Fourie, P. B., Donald, P. R., Padayatchi, N., Rustomjee, R., Levin, J.,
et al. (2005). The early bactericidal activities of rifampin and rifapentine in
pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 172, 128–135. doi:
10.1164/rccm.200411-1557OC
van Niekerk, C., and Ginsberg, A. (2009). Assessment of global capacity to conduct
tuberculosis drug development trials: do we have what it takes? Int. J. Tuberc.
Lung Dis. 13, 1367–1372.
Wayne, L. G. (1976). Dynamics of submerged growth of Mycobacterium
tuberculosis under aerobic andmicroaerophilic conditions.Am. Rev. Respir. Dis.
114, 807–811.
Frontiers in Microbiology | www.frontiersin.org 9 June 2015 | Volume 6 | Article 641
Hu et al. High-dose rifampicin kills persisters
Wayne, L. G. (1977). Synchronized replication of Mycobacterium tuberculosis.
Infect. Immun. 17, 528–530.
Wayne, L. G. (1994). Dormancy of Mycobacterium tuberculosis and
latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13, 908–914. doi:
10.1007/BF02111491
World Health Organization [WHO]. (2010). WHO global tuberculosis
control report 2010. Summary. Cent. Eur. J. Public Health
18, 237.
Yew, W. W., and Leung, C. C. (2006). Antituberculosis drugs and
hepatotoxicity. Respirology 11, 699–707. doi: 10.1111/j.1440-1843.2006.
00941.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Hu, Liu, Ortega-Muro, Alameda-Martin, Mitchison and Coates.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 10 June 2015 | Volume 6 | Article 641
